Stoke Therapeutics, Inc.

STOK

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001623526

SEC filings (opens in a new tab)

In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 10, 2026: $1.78B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $1.05M in total: 7
13F holdersQ2 2026, +1 vs. previous quarter: 197
13F valueReported value at the end of Q2 2026: $2.49B
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $184.4M; +404.5% year over year
Net income, FY2025: -$6.88M; No comparable prior period
Free cash flow, FY2025: $44.9M; No comparable prior period
Revenue, Q3 FY2026: $11.3M; +5.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $6.88M (3.7% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 10.7M; Shares sold short
Change: +465.6K; +4.5% vs. previous
Days to cover: 6.75; At average daily volume

Superinvestors holding STOK, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding STOK at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Stoke Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 4, 2026 (view filing)4:05 PM ET	Nov 2	2 days	Ticho BarryCHIEF MEDICAL OFFICER	SSale	−7.20K	$26.39	−$189.9K	−37.8%11.9K after	2 lots10b5-1
Oct 2, 2026 (view filing)5:37 PM ET	Oct 2	Same day	Allan JonathanGENERAL COUNSEL & CORP SEC	SSale	−627	$26.33	−$16.5K	−3.0%20.6K after	10b5-1
Oct 2, 2026 (view filing)5:35 PM ET	Oct 1	1 day	Ticho BarryCHIEF MEDICAL OFFICER	SSale	−1.05K	$26.16	−$27.5K	−5.2%19.1K after	10b5-1
Sep 3, 2026 (view filing)4:17 PM ET	Sep 1	2 days	Ticho BarryCHIEF MEDICAL OFFICER	SSale	−5.54K	$30.67	−$170.1K	−21.6%20.1K after	2 lots10b5-1
Aug 18, 2026 (view filing)8:29 PM ET	Aug 18	Same day	Ticho BarryCHIEF MEDICAL OFFICER	SSale	−4.77K	$32.03	−$152.7K	−15.7%25.7K after	2 lots
Aug 18, 2026 (view filing)8:28 PM ET	Aug 18	Same day	Kaye Edward M. MDDirector	SSale	−12.6K	$32.03	−$402.5K	−9.2%124.6K after	2 lots
Aug 18, 2026 (view filing)8:27 PM ET	Aug 18	Same day	Allan JonathanGENERAL COUNSEL & CORP SEC	SSale	−2.86K	$32.03	−$91.6K	−11.9%21.2K after	2 lots
Aug 5, 2026 (view filing)4:17 PM ET	Aug 3	2 days	Ticho BarryCHIEF MEDICAL OFFICER	SSale	−7.18K	$29.04	−$208.4K	−26.0%20.4K after	2 lots10b5-1
Jul 6, 2026 (view filing)4:10 PM ET	Jul 1	5 days	Ticho BarryCHIEF MEDICAL OFFICER	SSale	−7.23K	$32.66	−$236.1K	−20.8%27.6K after	2 lots10b5-1
Jun 18, 2026 (view filing)	Jun 16	2 days	Allan JonathanGENERAL COUNSEL & CORP SEC	SSale	−1.46K	$29.95	−$43.6K	−7.5%18.1K after	10b5-1

Top 10 13F holders, Q2 2026

See all 197 holders

The largest institutional positions in Stoke Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding STOK in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	5,877,357	$192.3M	0.00%	+491,643+9.1%	Added
RTW Investments, LP	5,623,525	$184.0M	1.57%	00.0%	Unchanged
FMR LLC	5,313,100	$173.8M	0.01%	−70,566−1.3%	Reduced
Lynx1 Capital Management LP	4,038,404	$132.1M	15.27%	−725,269−15.2%	Reduced
Redmile Group, LLC	3,945,920	$129.1M	8.67%	−218,200−5.2%	Reduced
Wellington Management Group LLP	3,519,301	$115.2M	0.02%	+423,601+13.7%	Added
Morgan Stanley	3,452,795	$113.0M	0.01%	+29,515+0.9%	Added
Baker Bros. Advisors LP	3,336,697	$109.2M	0.55%	00.0%	Unchanged
Toronto Dominion Bank	3,173,258	$103.8M	0.17%	00.0%	Unchanged
State Street Corp	2,852,240	$93.3M	0.00%	+575,728+25.3%	Added

Holders of 5% or more of STOK

See all 9 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Stoke Therapeutics, Inc..

Largest holders of STOK from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
RTW Investments, LP	13G/A	9.90%5.94M shares	−0.09 ppfrom 9.99%	Feb 12, 20216 filings	May 15, 2026	SEC
FMR LLC	13G/A	7.50%4.82M shares	−1.00 ppfrom 8.50%	Feb 8, 202110 filings	Nov 5, 2026	SEC
BlackRock, Inc.	13G/A	6.80%3.73M shares	+1.00 ppfrom 5.80%	Apr 16, 20252 filings	Oct 17, 2025	SEC
Redmile Group, LLC	13G/A	6.70%4.16M shares	−1.30 ppfrom 8.00%	Feb 16, 20217 filings	May 15, 2026	SEC
Lynx1 Capital Management LP	13G/A	6.50%4.04M shares	−1.60 ppfrom 8.10%	Nov 6, 20236 filings	Aug 14, 2026	SEC